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Asthma is a prevalent and serious health problem in Korea. Recently, the Korean Asthma Guideline has been updated 
by The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) in an effort to improve the clinical 
management of asthma. This guideline focuses on adult patients with asthma and aims to deliver up to date scientific 
evidence and recommendations to general physicians for the management of asthma. For this purpose, this guideline 
was updated following systematic review and meta-analysis of recent studies and adapting some points of international 
guidelines (Global Initiative for Asthma [GINA] report 2014, National Asthma Education and Prevention Program 
[NAEPP] 2007, British Thoracic Society [BTS/SIGN] asthma guideline 2012, and Canadian asthma guideline 2012). 
Updated issues include recommendations derived using the population, intervention, comparison, and outcomes 
(PICO) model, which produced 20 clinical questions on the management of asthma. It also covers a new definition of 
asthma, the importance of confirming various airflow limitations with spirometry, the epidemiology and the diagnostic 
flow of asthma in Korea, the importance and evidence for inhaled corticosteroids (ICS) and ICS/formoterol as a 
single maintenance and acute therapy in the stepwise management of asthma, assessment of severity of asthma and 
management of exacerbation, and an action plan to cope with exacerbation. This guideline includes clinical assessments, 
and treatment of asthma–chronic obstructive pulmonary disease overlap syndrome, management of asthma in specific 
conditions including severe asthma, elderly asthma, cough variant asthma, exercise-induced bronchial contraction, etc. 
The revised Korean Asthma Guideline is expected to be a useful resource in the management of asthma.
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Background
Asthma is an inflammatory airway disease that affects 
about 30 billion people worldwide1. The prevalence of asthma 
in Korea in adults was studied in 1998 by The Korean Acad-
emy of Tuberculosis and Respiratory Diseases (KATRD); that 
study revealed that 12.8% of 8,823 adults had some form of 
asthma2. Despite the high prevalence and clinical importance 
of asthma, the Korean Asthma Guideline had not been updat-
ed since November 20053 while the Korean Asthma Guideline 
was first published in 2000. 
Recently, several of important results on the epidemiology, 
pathophysiology, treatment, and management of asthma 
have been reported. Therefore, it was necessary to revise the 
Korean guideline based on updated knowledge and share 
the guideline with all physicians who manage patients with 
asthma. This review aims to summarize the major changes to 
the updated Korean Asthma Guideline for adults.
Introduction to the  
Korean Asthma Guideline 2014
The Korean Asthma Guideline 2014 is targeted to all doc-
tors who manage patients with asthma in daily practice4. The 
Korean guideline emphasizes that asthma is characterized by 
respiratory symptoms such as wheezing, shortness of breath, 
tightness in the chest, and coughing, accompanied by variable 
expiratory airflow limitation. Based on the characteristics of 
asthma, the guideline focuses on the importance of identify-
ing reversible or variable airflow limitation using spirometry. 
The Korean guideline addresses 20 key questions selected us-
ing the population, intervention, comparison, and outcomes 
(PICO) method that aid in the treatment of asthma and pres-
ents evidence-based recommendations made after intensive 
systematic review and meta-analysis of recently updated 
PICO reports. It also adapts some points of international 
guidelines (Global Initiative for Asthma [GINA] report 20145, 
National Asthma Education and Prevention Program [NAEPP] 
20076, British Thoracic Society [BTS/SIGN] 20127, Canadian 
Asthma Guideline 20128). 
The updated Korean Asthma Guideline covers the new 
definition of asthma, the epidemiology of asthma in Korea, the 
diagnostic flow of asthma, treatment recommendations based 
on updated evidence including the importance of and evi-
dence for inhaled corticosteroids (ICS) and ICS/formoterol as 
single maintenance and reliever therapy in the stepwise man-
agement of asthma, the concept, diagnosis, and treatment of 
asthma–chronic obstructive pulmonary disease overlap syn-
drome, assessment of severity and management of asthma 
exacerbation, and an action plan to cope with asthma exac-
erbation. The Korean guideline also covers the symptoms of 
asthma in specific conditions including severe asthma, asth-
ma in elderly people, cough variant asthma, exercise-induced 
bronchial constriction, occupational asthma, management in 
a perioperative period or pregnancy, and comorbidities. 
An appendix contains discussion on practical methods for 
the diagnosis of asthma such as spirometry, peak flow meter, 
and bronchial provocation tests. Inhaled medications and de-
vices available in Korea for treating asthma are also discussed. 
Finally, indications for the use of various medications issued 
by the National Health Insurance Service are described.
Methods
A steering committee and a scientific committee for the Ko-
rean Asthma Guideline were composed of 50 pulmonologists 
from different areas of the country. The guideline was devel-
oped by de novo process as well as adaptation of international 
asthma guidelines, and was peer reviewed. Specialists in 
systematic review and meta-analysis were also involved dur-
ing the entire period of guideline development. After search-
ing three databases (The National Guideline Clearinghouse, 
http://www.guideline.gov/; the Guideline International Net-
work, http://www.g-i-n.net/library/international-guidelines-
library; and the Trip database, https://www.tripdatabase.
com), guidelines satisfying the following criteria were selected 
for adaptation: (1) guidelines developed in a country similar 
to Korea in terms of climate and region; (2) international 
guidelines or guidelines developed by international groups; (3) 
guidelines developed or updated since 2011; (4) guidelines for 
adults; and (5) guidelines containing general information on 
the diagnosis, treatment, and management of asthma.
Finally, four guidelines from GINA, NAEPP, SIGN, and Can-
ada were selected after using the AGREE II method (http://
www.agreetrust.org/agree-ii/)9. A scientific committee devel-
oped key questions related to the management of asthma.
If the key questions agreed with the selected guidelines with 
a very high quality of evidence, the Korean guideline includes 
them. If the key questions did not appear in the selected guide-
lines or were out of date, new recommendations were devel-
oped using PICO after systematic review. Systematic review 
involved searching databases including Medline (http://www.
ncbi.nlm.nih.gov/pubmed), EMBASE (https://www.embase.
com), and the Cochrane library (http://www.cochranelibrary.
com/). The analysis included only data gathered from ran-
domized controlled studies and systematic reviews.
Evidence and strength of recommendation for each key 
question was determined with the Grading of Recommenda-
tions, Assessment, Development, and Evaluation (GRADE) 
method10,11. The quality of evidence was classified as ‘high,’ 
‘moderate,’ ‘low,’ ‘very low,’ or ‘expert opinion.’ The strength of 
each recommendation was classified as ‘strong’ or ‘weak.’ 
The Korean Asthma Guideline was circulated and approved 
for publication by the following organizations, which may 
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have conflicts of interest: the Korean Asthma and Allergy So-
ciety, the Korean Medical Association, the Korean Physicians’ 
Association, the Korean Academy of Family Medicine, the Ko-
rean General Physician Association, the Korean Association of 
Internal Medicine, the Korean Nurse Association, the Health 
Insurance Review and Assessment Service, the National 
Health Insurance Service, the Ministry of Health and Welfare, 
and the Korean Centers for Disease Control and Prevention.
Twenty key questions developed using PICO were issued 
following systematic review and finalizing of recommenda-
tions. They are as follows:
  1) Are ICS the best pharmacologic agent for maintenance 
of asthma in adults? 
  2) In step 3 of stepwise approaches to asthma control, is 
an inhaled long acting beta-2 agonist (LABA) the opti-
mal first choice as an add-on therapy in patients with 
asthma that is not well controlled with low doses of 
ICS?
  3) In step 3 of stepwise approaches to asthma control, is it 
effective to add leukotriene receptor antagonists (LTRA) 
to the treatment regimen of asthma patients whose dis-
ease is not well controlled with low doses of ICS? 
  4) In step 3 of stepwise approaches to asthma control, is it 
effective to increase the medium recommended dose 
of ICS for asthma patients whose disease is not well 
controlled with low doses of ICS? 
  5) Is combination therapy with LABA more effective than 
LTRA add-on therapy in asthma patients whose disease 
is not well controlled with low doses of ICS? 
  6) Can budesonide/formoterol combination therapy be 
used as a rescue therapy as well as a maintenance ther-
apy? Does it decrease the frequency of acute asthma 
attacks and improve asthma symptoms at relatively low 
doses? 
  7) In step 5 of stepwise approaches to asthma control, is 
oral corticosteroid effective in combination with other 
controller medications?
  8) Is LTRA more effective than ICS for controlling asthma 
in elderly patients with asthma?
  9) Is it effective to add tiotropium to the treatment regi-
men of patients whose disease is not well controlled 
with ICS/LABA?
10) Is bronchial thermoplasty effective in patients with se-
vere asthma?
11) Is the prophylactic use of macrolide effective in con-
trolling asthma and preventing acute exacerbation of 
asthma?
12) Do systemic steroids decrease the mortality, recur-
rence, hospital admission rate, and use of rescue medi-
cations in patients with acute exacerbation?
13) Is it more effective to administer both short-acting beta-
2 agonists (SABA) and ipratropium bromide through a 
nebulizer than it is to administer SABA alone in cases of 
acute exacerbation?
14) Is there any difference in efficacy between treating 
asthma with pressurized metered dose inhaler (pMDI)+ 
spacer versus a nebulizer in patients with mild to mod-
erate exacerbation of asthma?
15) Does intravenous aminophylline have any additional 
benefit in controlling acute exacerbation of bronchial 
asthma when it is added to the standard treatment of 
inhaled bronchodilators and steroids?
16) Is nebulized magnesium therapy effective in controlling 
acute exacerbation of bronchial asthma?
17) Is non-invasive positive pressure ventilation (NPPV) 
therapy effective in the treatment of acute respiratory 
distress following severe exacerbation of bronchial 
asthma?
18) Does subcutaneous immunotherapy have any clinical 
benefit compared with a placebo in controlling allergic 
bronchial asthma?
19) Is inhaled SABA effective in the treatment of exercise-
induced bronchoconstriction when it is used just be-
fore exercise?
20) Is ICS effective and safe to use in pregnant patients with 
asthma?
Summary of Major Updates to the 
Korean Asthma Guideline
1. Definition of asthma
“Asthma is a heterogeneous disease characterized by 
chronic airway inflammation. Symptoms include wheezing, 
shortness of breath, chest tightness, and cough which are 
variable over time and in intensity and accompanied by vari-
able expiratory airflow limitation.” This definition stresses the 
typical respiratory symptoms and associated variable airflow 
limitation measured objectively.
2. Prevalence, mortality, and burden of asthma 
Asthma is a very common disease worldwide and its preva-
lence is increasing. The prevalence of asthma in Korea has 
been increasing, especially in children and elderly people. The 
prevalence of asthma varies in different studies because of dif-
ferences in measurement methods. The prevalence of asthma 
in Korea was 12.8% in 1998 as reported by KATRD following a 
nation-wide survey given to 8,823 adults that asked about the 
presence of wheeze in the previous 12 months2. When the cri-
teria were restricted to the cases satisfying the questionnaire 
and provocation test, the prevalence was 3.4%. In the GINA 
report (2004), the reported prevalence of asthma in Korea 
was 3.9%, which was lower than the prevalence in the United 
States (10.9%) or Japan (6.7%)12.
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According to the Korean National Health and Nutrition Ex-
amination Survey (KNHANES), the prevalence of physician-
diagnosed asthma increased to 2.0% in 2008 from 0.7% in 
199813.
As assessed from Korean national insurance data, the 
prevalence of asthma was 4.7% in 2008; asthma was defined 
as the presence of an asthma code and history of treatment. 
Occupational asthma is reported to account for up to 10% of 
total cases of asthma14.
The mortality rate associated with asthma and an accurate 
estimate of the total number of asthma cases has not been 
reported in Korea. Mortality caused by chronic lower respira-
tory diseases including asthma decreased from 22.6 cases 
per 100,000 people in 2002 to 15.6 cases per 100,000 people 
in 2012. However, as most of the mortality occurred in elderly 
people (those over 60 years of age), mortality of asthma is ex-
pected to be much lower in the younger population15.
In a report based on Korean insurance claim data, the total 
cost of asthma-related health care was about 742,000,000 dol-
lars, which was used to treat 2,270,000 patients with asthma in 
200814. The direct cost was 64.5%, while the indirect cost was 
35.5%. Medical cost per person increased with age. 
3. Diagnosis, assessment, and differential diagnosis of 
asthma 
Asthma can be diagnosed by identifying the typical charac-
teristics of respiratory symptoms and variable airflow limita-
tion, as shown in Table 1. Details reflecting variable expiratory 
airflow limitation are included in the guideline; it adopted the 
recently updated GINA guidelines. Briefly, variable expiratory 
flow limitation can be measured with a bronchodilator revers-
ibility test, variability in peak expiratory flow (PEF), significant 
changes in lung function after 4 weeks of anti-inflammatory 
treatment, and bronchial provocation tests.
Initial diagnostic flow shown in Figure 1 is based on the 
diagnostic criteria given in Table 1. However, it includes clini-
cal settings in which spirometry/PEF meters and reversibility 
Table 1. Diagnosis of asthma based on clinical characteristics and variable airflow limitation
Diagnostic feature Criteria for making diagnosis of asthma 
History of variable respiratory symptoms
Wheezing, shortness of breath, chest tightness, and 
coughing
Generally more than one type of respiratory symptom (in adults, isolated 
cough is seldom due to asthma)
Symptoms vary over time and in intensity
Symptoms are often worse at night or upon awakening 
Symptoms are often triggered by exercise, laughter, allergens, or cold air
Symptoms often appear or worsen with viral infections
Confirmed variable expiratory airflow limitation
Documented excessive variability in lung function (one 
or more of the tests below) and documented airflow 
limitation
As the greater the variations, or the more occasions excess variation is 
seen, the diagnosis of asthma is more confident.
At least once during the diagnostic process when FEV1 is low, confirm 
that FEV1/FVC is reduced (normal levels are >0.75–0.80 in adults)
Positive BD reversibility test (more likely to be positive if 
BD medication is withheld before test: SABA ≥4 hours, 
LABA ≥15 hours)
Increase in FEV1 of >12% and >200 mL from baseline, 10–15 minutes after 
200–400 µg albuterol or equivalent (greater confidence if increase is 
>15% and >400 mL)
Excessive variability in twice-daily PEF over 2 weeks Average daily diurnal PEF variability >10%
Significant increase in lung function after 4 weeks of  
anti-inflammatory treatment
Increase in FEV1 of >12% and >200 mL (or increase in PEF of >20%) 
from baseline after 4 weeks of treatment, in the absence of respiratory 
infections
Positive exercise challenge test* Fall in FEV1 of 10% and >200 mL from baseline
Positive bronchial challenge test Decrease in FEV1 from baseline of ≥20% with standard doses  
of methacholine or histamine, or ≥15% with standardized hyperventilation, 
hypertonic saline or mannitol challenge
Excessive variation in lung function between visits  
(less reliable)
Variation in FEV1 of >12% and >200 mL between visits, in the absence  
of respiratory infections
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by a history of respiratory symptoms 
such as wheezing, shortness of breath, chest tightness, and coughing that vary over time and in intensity, together with variable expiratory 
airflow limitation.
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; BD: bronchodilator; SABA: short-acting beta-2 agonists; LABA: long 
acting beta-2 agonist; PEF: peak expiratory flow.
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tests are not available and clinical diagnosis via therapeutic 
trials with ICS and SABA is needed. In such cases, the guide-
line recommends that diagnostic tests should be performed 
within 1–3 months. 
When physicians meet with their patients, they should as-
sess the extent of asthma symptom control over the last 4 
weeks. ‘Controlled’ is defined when patients answered “no” 
to all the questions below; ‘partly controlled’ is defined when 
patients answered “no” to one or two of the questions, and ‘un-
controlled’ means that patients answered “yes” to three or four 
of questions.
  1) Daytime asthma symptoms more than twice per week?
  2) Night waking due to asthma?
  3) Rescue inhaler needed for treatment of acute symp-
toms more than twice per week?
  4) Any activity limitation due to asthma?
Tools including the asthma control test (ACT; http://www.
asthmacontrol.com) and the asthma control questionnaire 
(ACQ) can be useful in distinguishing between different levels 
of symptom control. ACT score ranges from 5 to 25. Scores of 
20–25 indicate well-controlled asthma, while scores of 5–15 
indicate very poorly controlled asthma. 
Besides assessment of control status, the guideline empha-
sizes the importance of assessing inhaler techniques, adher-
ence to treatment, adverse events, comorbidity, and future 
risk. A recent history of exacerbation, poor adherence to drug 
regimens, inadequate inhaler techniques, poor spirometric 
data, smoking, eosinophilia, fixed airflow limitation, and ad-
verse events all increase the future risk of asthma attacks.
As the most useful diagnostic parameter for anticipating fu-
ture risk in patients with asthma is lung function, tests for lung 
function are mandatory 3–6 months after the beginning of 
treatment and periodically thereafter, as well as at the time of 
initial diagnosis. A discordance between symptoms and lung 
function may indicate a need for further tests.
4. Treatment and prevention
This guideline updated the recommendations for medi-
cal treatment and prevention of asthma based on updated 
evidence in order to improve the management of asthma, 
minimize the future risk of exacerbations, reduce fixed airflow 
limitation, and reduce the adverse effects of treatment.
Medications for control of asthma can be subdivided into 
‘controller’ and ‘reliever’ types. A controller should be used 
consistently over the long term to attenuate airway inflamma-
tion, while a reliever should be used as needed to relieve acute 
symptoms via rapid bronchodilation. Controllers include ICS, 
the combination of ICS and a LABA, anti-leukotriene agents, 
systemic steroids, and anti-IgE antibody. 
Because inhaled medications directly deliver drugs to 
affected airways in high concentrations while minimizing 
systemic effects, inhaled medication is the first choice of treat-
ment for asthma.
Until now, ICS has been the most effective controller medi-
cation with anti-inflammatory action16-19. Therefore, ICS is 
Figure 1. Initial diagnostic flow to be used in clinical practice. PEF: peak expiratory flow; ICS: inhaled corticosteroids; prn: as needed; SABA: 
short acting beta-2 agonist.
Patients with respiratory symptoms
Are the typical symptoms of asthma?
Detailed history & physical examination
Does history/examination supports the
diagnosis of asthma?
Further history & tests for alternative diagnosis
Is alternative diagnosis confirmed?
Spirometry/PEF with reversibility test
Do the results support the diagnosis of asthma?
Trial of treatment for most
likely diagnosis or referral
Treat for alternative diagnosisTreat for asthma
Empirical treatment with ICS and SABA
Review response





Repeat on another occasion
or arrange other tests




DK Kim et al.
116 Tuberc Respir Dis 2016;79:111-120 www.e-trd.org
recommended for all patients with asthma if it is available 
and the patient does not experience adverse effects (evidence, 
high; recommendation, strong). The Korean guideline de-
scribes the clinical effects of new therapeutic agents including 
anti-interleukin (IL)-5 and anti–IL-13. Based on positive clini-
cal results of use of tiotropium, it should be considered as an 
additional medication in cases where asthma is not controlled 
with ICS/LABA (evidence, high; recommendation, strong).
This guideline adopted a cyclic approach consisting of 
assessment, adjustment, and review of response5. After as-
sessing control status, a stepwise approach is recommended 
to achieve ‘controlled asthma’ (Table 2). The role of ICS as a 
preferred controller is emphasized and it should be used in 
all steps. Even in step 1, ICS should be considered as an alter-
native controller option. Depending on the status of disease 
control, ICS/LABA is used in steps 3 and above20. LABA is 
preferentially recommended for patients whose disease is not 
well controlled with low doses of ICS (evidence, high; recom-
mendation, strong). One of the focus points in the guideline is 
that low doses of an ICS/formoterol combination can be used 
as an as-needed reliever in addition to inhaled short acting 
beta agonists (evidence, high; recommendation, strong)21.
Prior to stepping up asthma treatment, physicians should 
always assess the level of asthma control, adherence to treat-
ment, and inhaler techniques. Once treatment is stepped 
up, treatment response should be assessed for at least 2–3 
months. If asthma is well controlled for 3 months, stepping 
down treatment can be considered. In stepping down, usually 
the dosage of ICS is decreased by 25%–50%. If low dose ICS/
LABA is maintained, the frequency of ICS/LABA use can be 
decreased to once daily. When stepping down treatment, in-
structions and asthma action plans should be provided to the 
patients. 
If the patients suffer from frequent exacerbation despite 
maximal and optimal medical treatment, efforts to identify 
and treat modifiable risk factors can reduce the risk of exacer-
bation.
5. Management of acute exacerbation
Exacerbation of asthma, or ‘flare-up,’ is defined as acute or 
sub-acute worsening of symptoms and lung function com-
pared to the patient’s normal status and requires a change in 
treatment22. 
The first step in managing acute exacerbation is to assess 
the severity of exacerbation with a brief focused history and 
physical examination, accompanied by promptly initiation of 
treatment. If the patient talks in words rather than full sentenc-
es, sits hunched forwards, is agitated, breathes rapidly (>30/
min), and/or uses accessory muscles for breathing, severe 
exacerbation is present. Tachycardia (>120/min), desatura-
tion (<90%), or decreased PEF (≤50% of predicted or best) are 
also sign of a severe flare-up and SABA, oxygen therapy, and/
or systemic steroids should be administered.
Mild exacerbation may be managed in primary care centers 
and patients may be given a written action plan to prevent fu-
ture flare-ups. However, written action plans should be given 
only if the patient can understand and comply with them. In 
moderate exacerbation, inhaled SABA is effective when it is 
administered every 20 minutes for one hour. Afterwards, the 
dose and interval of SABA may be altered depending on the 
severity of exacerbation. As systemic steroids are effective in 
decreasing mortality, recurrence, hospitalization, and use of 
relievers, early administration of systemic steroids (predniso-
lone 1 mg/kg, maximum 50 mg/24 hours) is recommended 
when exacerbation occurs23,24. Oxygen is usually administered 
to achieve arterial oxygen saturation of 93%–95%. 
Prior to discharge after exacerbation, arrangements for 
medications including 5–7 days of systemic steroids, educa-
tion on inhaler techniques, and a written asthma action plan 
should be made.
6. Asthma in specific conditions
The Korean guideline covers the management of asthma 
in specific conditions including severe asthma, asthma in 
elderly patients, cough variant asthma, exercise-induced bron-
choconstriction, occupational asthma, and management of 
Table 2. Stepwise approach to control asthma
Step Preferred controller Other controller options Reliever
Step 1 - Low dose ICS As-needed SABA
Step 2 Low dose ICS LTRA
Low dose theophylline
Step 3 Low dose ICS/LABA Medium/high dose ICS
Low dose ICS+LTRA (or +theophylline)
As-needed SABA or low dose ICS/formoterol
Step 4 Medium/high ICS/LABA High dose ICS+LTRA (or +theophylline)
Step 5 Refer for add-on treatment Add low dose oral corticosteroids
ICS: inhaled corticosteroids; SABA: short-acting beta2 agonist; LTRA: leukotriene antagonist; LABA: long acting beta-2 agonist.
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asthma in perioperative periods, pregnancy, and the presence 
of comorbid diseases. The key points are as follows. 
First, in cases of severe asthma that is not controlled with 
high-dose ICS and one or more other controllers, add-on 
treatment options may be considered.
Add-on therapy with tiotropium is recommended for pa-
tients with severe asthma that is not controlled by an ICS/
LABA combination (evidence, high; recommendation, 
strong)25-27. Leukotriene receptor antagonists can be also be 
considered as an add-on therapy in cases of severe asthma 
that is not well controlled with ICS/LABA28. High doses of ICS 
and systemic corticosteroids may be considered to control 
severe asthma that is not responsive to lower doses of cortico-
steroids. However, systemic steroids should maintained at the 
lowest possible dose.
Anti-IgE therapy for allergic severe asthma may be consid-
ered in order to reduce exacerbation and steroid dose and 
improve quality of life29,30. 
Bronchial thermoplasty may be a treatment option for im-
proving quality of life and reducing the frequency of exacerba-
tion in symptomatic patients with moderate to severe asthma 
that does not respond to maximal medication doses31,32.
Although prophylactic macrolides therapy has been report-
ed to reduce the frequency of exacerbation in non-eosinophlic 
severe asthma33,34, it is generally not recommended as a main-
tenance therapy to control asthma and prevent exacerbation.
As asthma may be neglected or may overlap with other 
conditions in elderly people, careful attention should be paid 
when diagnosing asthma in elderly patients. The general prin-
ciples for diagnosis and management are applicable to this 
population.
Cough variant asthma is a subtype of asthma that includes 
bronchial hyper-responsiveness as a typical feature. ICS is the 
mainstay in treating cough variant asthma.
In patients with exercise-induced bronchoconstriction, in-
haled SABA is recommended prior to exercise as needed if the 
patient’s symptoms occur during or after exercise and there is 
no other risk factor for exacerbation35.
In all patients with adult-onset asthma, an occupational his-
tory should be taken. The identification and removal of occu-
pational sensitizers is necessary in patients with occupational 
asthma.
Aspirin-exacerbated respiratory disease involves nasal con-
gestion, anosmia, chronic rhinosinusitis with nasal polyps, and 
hypersensitivity to aspirin or nonsteroidal anti-inflammatory 
drugs. ICS is the mainstay of treatment and desensitization to 
aspirin can significantly improve quality of life, reduce symp-
toms, and decrease formation of nasal polyps and the need for 
oral corticosteroids. 
In perioperative asthma patients, meticulous attention is 
necessary to track the status of asthma control and reduce 
perioperative complications. All patients should be main-
tained on regular controller therapy in perioperative periods 
and additional preventative therapy may reduce asthma-
related operative complications.
During pregnancy, one-third of pregnant women with asth-
ma find that their asthma worsens, particularly in the second 
trimester36, and the advantages of managing asthma properly 
outweighs any potential risks of inhaled medications. Regular 
ICS use is recommended in women with asthma during preg-
nancy (evidence, high; recommendation, strong).
Weight reduction may help to control asthma in patients 
with comorbid obesity. Therefore, weight reduction should 
be included in the treatment plan along with ICS in obese pa-
tients with asthma. 
Rhinitis may be preceded or accompanied by asthma and 
is a risk factor for asthma. Appropriate management of rhinitis 
can reduce the symptoms of asthma.
7. Education and asthma action plan
It is important to establish an interactive physician-patient 
relationship, discuss objectives of asthma treatment, and 
provide individualized education for self-management. This 
guideline recommends providing patients with individualized 
written proper asthma action plans upon initial diagnosis and 
at the time of discharge from the clinical ward or emergency 
room. 
Summary on Key Recommendations 
Arrived at through Systematic Review
  1) ICS are the most effective drugs for general control of 
asthma and their use is recommended for all patients 
with asthma (evidence, high; recommendation, strong). 
  2) In step 3 of the stepwise approach to asthma control, 
inhaled LABA should be added to the treatment regi-
mens of patients whose disease is not well controlled 
with low doses of ICS (evidence, high; recommenda-
tion, strong).
  3) In step 3 of the stepwise approach to asthma control, 
LTRA is recommended as an add-on therapy in pa-
tients whose disease is not well controlled with low 
doses of ICS (evidence, high; recommendation, strong).
  4) In step 3 of the stepwise approach to asthma control, 
it is recommended that the dose of ICS is increased to 
medium levels in patients whose disease is not well 
controlled with low doses of ICS (evidence, high; rec-
ommendation, strong).
  5) In cases of asthma that is not controlled with ICS alone, 
combination therapy with LABA is more effective than 
add on therapy with LTRA (evidence, high; recommen-
dation, strong).
  6) Combination drugs with formoterol and budesonide 
can be used as controllers and relievers because they 
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reduce the risk of exacerbation and relieve symptoms 
of asthma (evidence, high; recommendation, strong).
  7) In step 5 of the stepwise approach to asthma control, it 
is recommended that the minimum possible dose of 
oral corticosteroids is used (evidence, high; recommen-
dation, strong).
  8) In elderly asthma patients (those over 65 years of age), 
LTRA can be considered instead of ICS (evidence, low; 
recommendation, weak). 
  9) Tiotropium is recommended as an add-on therapy for 
asthma patients whose disease is not well controlled 
with a combination of ICS and LABA (evidence, high; 
recommendation, strong).
10) Bronchial thermoplasty is a viable treatment option for 
patients with moderate to severe asthma (evidence, 
low; recommendation, weak). 
11) Macrolide is not recommended as a maintenance 
therapy in patients with severe asthma (evidence, high; 
recommendation, weak).
12) Systemic corticosteroids should be administered as 
early as possible to asthma patients with exacerbation 
because they can reduce the mortality, recurrence, 
admission, and use of relievers (evidence, high; recom-
mendation, strong).
13) In patients with exacerbation who visit the emergency 
room, combined inhalation therapy with SABA and ip-
ratropium bromide using a nebulizer is recommended 
because this technique produces a greater degree of 
bronchodilation and a shorter duration of recovery 
(evidence, high; recommendation, strong). 
14) In patients with exacerbation, the bronchodilatory ef-
fect of SABA given by pMDI with spacers or nebulizers 
is similar (evidence, high; recommendation, strong). 
15) Addition of intravenous aminophylline is not recom-
mended for asthma patients with exacerbation (evi-
dence, high; recommendation, strong).
16) Nebulized magnesium should not be given to asthma 
patients with exacerbation (evidence, low; recommen-
dation, strong).
17) Because the efficacy of NPPV for treatment of respira-
tory failure due to severe exacerbation of asthma has 
not been established, it should be considered with cau-
tion in treating exacerbation of asthma (evidence, low; 
recommendation, weak).
18) Subcutaneous allergen-specific immunotherapy 
can be used when a specific allergen causing clinical 
symptoms is identified in patients with difficult-to-treat 
asthma despite maximal medical treatment (evidence, 
high; recommendation, strong).
19) Inhaled SABA should be administered before exercise 
in patients with exercise-induced bronchoconstriction 
(evidence, high; recommendation, strong).
20) ICS should be used regularly in women with asthma 
during pregnancy (evidence, high; recommendation, 
strong).
Conclusion
The Korean Asthma Guideline has recently been revised 
to provide updated evidence-based treatment strategies to 
physicians who manage asthma. This guideline is targeted to 
improving the quality of asthma treatment and maximizing 
treatment efficacy; it is expected that the guideline will help 
minimize mortality and burden of this disease. Actively imple-
menting this guideline in the Korean healthcare system will 
help achieve the ultimate goals of managing asthma.
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